Advanced Code injection

Ontario Industry Updates

Interface Biologics Announces the Extension of its Licensing Agreement with Fresenius Medical Care

TORONTO, Canada, February 9, 2016 - Interface Biologics Inc. (IBI) is pleased to announce that Fresenius Medical Care, the worlds’ largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo™ technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).

Rna Diagnostics announces new study in chemotherapy efficacy in canine lymphoma

Rna Diagnostics Inc announced today a new study to investigate RDA as a predictor for chemotherapy efficacy in canine lymphoma in partnership with University of Guelph Institute for Comparative Cancer Investigation and the Mona Campbell Centre for Animal Cancer at the Ontario Veterinary College. This study of canine lymphoma is based on the success of an initial canine lymphoma study completed in 2014.

NOVADAQ Announces Fourth Quarter 2015 Preliminary Unaudited Revenues and Issues 2016 Revenue Guidance

TORONTO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Novadaq Technologies Inc. (“NOVADAQ” or the “Company”) (NVDQ) (NDQ.TO), the leading developer and provider of clinically relevant fluorescence imaging solutions for use in surgical and diagnostic procedures, announced today preliminary unaudited revenue for the fourth quarter of 2015 and provided 2016 revenue guidance ahead of its participation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. 

Moseda Announces Appointment of Experienced Healthcare Technology Executive

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 18, 2016) - Moseda Technologies Inc. (TSX VENTURE:MSD) ("Moseda" or the "Company"), a technology company focused on developing progressive mobile health (mHealth) and telemedicine solutions for institutional and home healthcare, is pleased to announce that it has appointed industry expert Dr. Lisa Crossley, PhD., P.Eng. as CEO and Director and Mr. Sameet Kanade as President and Chairman of the Board as the Company aims to ramp up its client acquisition strategy.

Sernova Corp to Present at the Biotech Showcase(TM) 2016 in San Francisco on January 13, 2016

Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, today announced that Dr. Philip Toleikis, Sernova’s President and CEO, will be providing a corporate update at the 8th annual Biotech Showcase Conference in San Francisco, CA, at 4:00 p.m. PST on January 13, 2016 in San Francisco, California.

In a full roster of business development meetings, Dr. Toleikis will also be updating key pharma and institutional audiences on the company's progress and future plans.

Launch of the second Canada-Chicago Mentoring Program (C2MP)

The Consulate General of Canada in Chicago successfully partnered in 2015 (testimonials included in our enclosed marketing document for the 2016 program) with the Chicago Innovation Mentors (CIM) to provide a comprehensive mentoring program for three Canadian life science and healthcare entrepreneurs. 
 
It is our pleasure to announce that the program has been renewed for 2016. The Consulate will again be able to funnel three Canadian start-ups through CIM’s mentoring program. 

Spectral to Present at the 20th International Conference on Advances in Critical Care Nephrology (AKI & CRRT) in San Diego

Spectral Medical Inc., a Phase III company developing the first therapy for patients with septic shock guided by a diagnostic, today announced that it will present at the upcoming 20th International Conference on Advances in Critical Care Nephrology (AKI & CRRT) conference in San Diego, California on February 18, 2015 during an interactive luncheon session.